BiotechTube
Aragen Life Sciences

Aragen Life Sciences

San Jose, United States· Est.
aragen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

Aragen Life Sciences is a privately held, revenue-generating CRDMO founded in 2001 and headquartered in San Jose, USA, with its global headquarters and major R&D/manufacturing campus in Hyderabad, India. The company leverages a global talent pool of over 4000 scientists, including 450+ PhDs, to serve a broad client base that includes 7 of the top 10 large pharma companies and over 100 biotechs. Its business model is centered on providing integrated, technology-enabled R&D and manufacturing services across drug delivery, biologics, and small molecules, aiming to accelerate client timelines from discovery to market.

Drug DeliveryBiologicsSmall Molecules

Technology Platform

Digital and AI-powered integrated CRDMO platform. Includes CHOMax™, an accelerated platform for DNA-to-IND-enabling clinical supply for biologics in ~10 months.

Funding History

1
Total raised:$25M
Series A$25M

Opportunities

The growing trend of biopharma outsourcing, especially for complex biologics, presents a major growth opportunity.
Its integrated CRDMO model and AI/digital focus allow it to compete on value and speed, not just cost.
The dual-shore (US-India) operational model is a key strategic advantage in accessing talent and markets.

Risk Factors

Faces intense competition from large global CDMOs and lower-cost regional players.
Geopolitical and operational risks associated with its significant footprint in India.
Reliance on a concentrated base of large pharma clients creates revenue concentration risk.

Competitive Landscape

Aragen competes in the global CRDMO market against large, publicly-traded players like Lonza, Catalent, and Thermo Fisher Scientific, as well as other India-based CDMOs like Syngene and Jubilant Biosys. Its differentiation lies in its fully integrated service model, strong biologics capabilities (e.g., CHOMax™), and its hybrid US-India structure offering both scientific proximity and cost efficiency.

More companies in Small Molecule Drugs →More companies in United States →